医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Quintiles’ Second Quarter 2013 Earnings Call Scheduled for Thursday, August 1st

2013年07月01日 PM09:25
このエントリーをはてなブックマークに追加


 

RESEARCH TRIANGLE PARK, N.C.

Quintiles Transnational Holdings Inc. (NYSE: Q) will release its financial results for the second quarter of 2013 on Thursday, August 1, 2013, before the market opens. An investor conference call will be held on Thursday, August 1, 2013 at 8:00 a.m. EDT.

To participate via telephone, please dial +1 (855) 484-7367 or +1 (631) 259-7541 outside the United States, approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible, live via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com.

An archived edition of the conference call will be available online at www.quintiles.com after 1:00 p.m. EDT on Thursday, August 1.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Click here to subscribe to Mobile Alerts for Quintiles.

CONTACT

Quintiles
Media Relations
Phil Bridges, +1-919-998-1653
Mobile:
+1-919-457-6347
phil.bridges@quintiles.com
or
Investor
Relations
Karl Deonanan, +1-919-998-2789
InvestorRelations@quintiles.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates